Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats

被引:9
作者
Testa, R
Ghia, M
Mattioli, F
Borzone, S
Caglieris, S
Mereto, E
Giannini, E
Risso, D
机构
[1] DIMI, Dept Internal Med, Gastroenterol Unit, I-16132 Genoa, Italy
[2] Univ Genoa, Pharmacol Unit, Genoa, Italy
[3] Univ Genoa, Inst Med Stat, Genoa, Italy
关键词
lidocaine; MEGX; cimetidine; glutathione; N-acetylcysteine; rats;
D O I
10.1111/j.1472-8206.1998.tb00945.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this work was to evaluate the effects of exogenous glutathione (GSH) and N-acetylcysteine (NAG) on the formation of monoethylglycinexylidide (MEGX) from lidocaine in rats with and without the administration of cimetidine. GSH and NAC were administered intraperitoneally (ip) (1 mmol/kg) 1 hour before treatment with cimetidine (0.5 mmol/kg) or saline, and 1 hr later all rats were injected ip with lidocaine (1 mg/kg). Blood samples were drawn 30 min after the lidocaine injection. MEGX and lidocaine serum concentrations were determined by means of fluorescence polarization immune-assay using the TDX system. Cimetidine produced a decrease in MEGX levels (from 210 +/- 18 to 164 +/- 13 ng/mL) and a parallel increase in lidocaine levels (from 73 +/- 22 to 172 +/- 47 ng/mL), consistent with cytochrome P-450 3A inhibition. Both GSH and NAC produced a significant decrease in MEGX levels (151 +/- 16 and 139 +/- 14 ng/mL, respectively), but no significant increase in lidocaine levels were found. As compared to the cimetidine group, pre-treatment using either GSH or NAC with cimetidine produced a marked decrease in lidocaine levels (37 +/- 27 and 63 +/- 28 ng/mL, respectively) and no modification of MEGX levels (155 +/- 12 and 165 +/- 22 ng/mL, respectively). These results suggest that GSH and NAC might accelerate the lidocaine metabolism while counteracting the inhibitory effect of cimetidine. (C) 1998 Elsevier, Paris.
引用
收藏
页码:220 / 224
页数:5
相关论文
共 19 条
[1]  
ARMITAGE P, 1994, STAT METHODS MED RES, P288
[2]   LIDOCAINE METABOLISM IN HUMAN-LIVER MICROSOMES BY CYTOCHROME-P450IIIA4 [J].
BARGETZI, MJ ;
AOYAMA, T ;
GONZALEZ, FJ ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) :521-527
[3]   N-ACETYL CYSTEINE ENHANCES THE RESPONSE TO INTERFERON-ALPHA IN CHRONIC HEPATITIS-C - A PILOT-STUDY [J].
BELOQUI, O ;
PRIETO, J ;
SUAREZ, M ;
GIL, B ;
QIAN, CH ;
GARCIA, N ;
CIVEIRA, MP .
JOURNAL OF INTERFERON RESEARCH, 1993, 13 (04) :279-282
[4]   CIMETIDINE AND OMEPRAZOLE HAVE DIFFERENT EFFECTS ON HEPATIC EXTRACTION OF LIDOCAINE IN RATS [J].
BRUCK, R ;
KREPEL, Z ;
BARMEIR, S .
GASTROENTEROLOGY, 1990, 99 (03) :857-859
[5]   DISPOSITION OF A FLOW-LIMITED DRUG (LIDOCAINE) AND A METABOLIC CAPACITY LIMITED DRUG (THEOPHYLLINE) IN LIVER-CIRRHOSIS [J].
COLLI, A ;
BUCCINO, G ;
COCCIOLO, M ;
PARRAVICINI, R ;
SCALTRINI, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (06) :642-649
[6]   INHIBITION OF MIXED-FUNCTION OXIDATIONS BY SUBSTRATES FORMING REDUCED CYTOCHROME-P-450 METABOLIC-INTERMEDIATE COMPLEXES [J].
FRANKLIN, MR .
PHARMACOLOGY & THERAPEUTICS PART A-CHEMOTHERAPY TOXICOLOGY AND METABOLIC INHIBITORS, 1977, 2 (01) :227-245
[7]  
HAUSLEITHNER V, 1992, Journal of Hepatology, V16, pS95
[8]  
IMAOKA S, 1990, J PHARMACOL EXP THER, V255, P1385
[9]  
KEENAGHAN J B, 1972, Journal of Pharmacology and Experimental Therapeutics, V180, P454
[10]  
NYBERG G, 1977, ACTA PHARMACOL TOX, V40, P337